Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis

Rawla, 2019, Epidemiology of prostate cancer, World J Oncol, 10, 63, 10.14740/wjon1191 Koo, 2018, Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review, Yonsei Med J, 59, 567, 10.3349/ymj.2018.59.5.567 Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Gillessen, 2018, Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002 Ahmed, 2012, Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer, Front Oncol, 2, 215 Decaestecker, 2014, Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence, Radiat Oncol Lond Engl, 9, 135, 10.1186/1748-717X-9-135 Tosoian, 2017, Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations, Nat Rev Urol, 14, 15, 10.1038/nrurol.2016.175 Jang, 2018, Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?, BJU Int, 121, 225, 10.1111/bju.13992 Rao, 2019, Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure?, Am Soc Clin Oncol Educ Book, 39, 309, 10.1200/EDBK_239041 Narita, 2019, Radical prostatectomy with and without neoadjuvant chemohormonal pretreatment for high-risk localized prostate cancer: a comparative propensity score matched analysis, Clin Genitourin Cancer, 17, e113, 10.1016/j.clgc.2018.09.019 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 Prayer-Galetti, 2007, Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer, BJU Int, 100, 274, 10.1111/j.1464-410X.2007.06760.x Sella, 2008, Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer, Urology, 71, 323, 10.1016/j.urology.2007.08.060 Cornford, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol, 71, 630, 10.1016/j.eururo.2016.08.002 Aluwini, 2020, Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting, Eur Urol Oncol, 3, 231, 10.1016/j.euo.2019.07.010 Soloway, 2002, Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results, J Urol, 167, 112, 10.1016/S0022-5347(05)65393-1 Shelley, 2009, A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma, Cancer Treat Rev, 35, 9, 10.1016/j.ctrv.2008.08.002 Mellado, 2009, Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer, Br J Cancer, 101, 1248, 10.1038/sj.bjc.6605320 Narita, 2012, World J Surg Oncol, 10, 1, 10.1186/1477-7819-10-1 Chi, 2008, Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer, J Urol, 180, 565, 10.1016/j.juro.2008.04.012 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol, 20, 686, 10.1016/S1470-2045(19)30082-8 Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396 Sydes, 2018, Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol, Ann Oncol, 29, 1235, 10.1093/annonc/mdy072 Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1